We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The MHRA hosted a live Ask Me Anything on how artificial intelligence (AI) is being regulated in healthcare.
Guidance on the steps manufacturers and suppliers can take to ease supply shortages.
Recommendations for prescribing methadone and buprenorphine to people in treatment for opioid dependence in England.
Safety leaflet on epilepsy medicines and pregnancy to help patients and their families understanding the risks.
Resources for World Antimicrobial Resistance Awareness Week (WAAW) and European Antibiotic Awareness Day (EAAD) for healthcare professionals in England.
Links to EU guidance, as it stood immediately before end of transition period.
Every year the MHRA receives requests for its staff to speak at conferences and other events across the world.
There are different regulations which apply to devices and equipment including hand gels and PPE (personal protective equipment)
This publication clarifies which regulatory guidelines should be followed, and which apply, in the development of phage therapeutic products.
Information on the implementation of changes to the licensing of medicines for human use in the UK following the agreement of the Windsor Framework.
Phase 2 of the Airlock will include seven additional technologies spanning AI-powered clinical note taking, advanced cancer diagnostics, eye disease detection tools, and obesity treatment support systems.
Outlining the principles for the management and oversight of the import of investigational medicinal products (IMPs) to Great Britain from listed countries.
Guidance on how to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in the UK.
Guidance on how to submit changes to labelling and patient information leaflets to MHRA.
Information relating to parallel imports and the implementation of the Windsor Framework.
Information on the implementation of changes to pharmacovigilance for medicines authorised in the UK following the agreement of the Windsor Framework.
Information about suspected side effects of e-cigarettes and how to report side effects.
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
This guidance clarifies the expectations on the application of the further pharmacovigilance provisions set out within the updated CIR 520/2012 for UK authorised products.
An overview of the legal requirements for children’s medicines that marketing authorisation holders (MAHs) need to abide by.
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).